Bancolombia S.A. (CIB) Analysts See $0.91 EPS; Last Week Fresenius Medical Care AG & Co. KGaA (FMS) Coverage

April 17, 2018 - By olga

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Logo

Analysts expect Bancolombia S.A. (NYSE:CIB) to report $0.91 EPS on May, 22.They anticipate $0.03 EPS change or 3.41% from last quarter’s $0.88 EPS. CIB’s profit would be $875.25 million giving it 13.73 P/E if the $0.91 EPS is correct. After having $1.26 EPS previously, Bancolombia S.A.’s analysts see -27.78% EPS growth. The stock increased 1.42% or $0.7 during the last trading session, reaching $49.97. About 316,818 shares traded. Bancolombia S.A. (NYSE:CIB) has risen 6.47% since April 17, 2017 and is uptrending. It has underperformed by 5.08% the S&P500.

Among 8 analysts covering Fresenius Medical (NYSE:FMS), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Fresenius Medical had 17 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Wednesday, July 5. Jefferies upgraded Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) on Friday, July 8 to “Hold” rating. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2. The firm earned “Sector Perform” rating on Wednesday, November 4 by RBC Capital Markets. The rating was maintained by Goldman Sachs with “Buy” on Tuesday, September 22. The firm earned “Hold” rating on Tuesday, May 30 by RBC Capital Markets. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, December 11. The firm earned “Buy” rating on Wednesday, December 20 by SunTrust. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, July 31. The firm earned “Overweight” rating on Monday, January 4 by JP Morgan. See Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) latest ratings:

20/12/2017 Broker: SunTrust Rating: Buy New Target: $62.0 Maintain
11/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $50.0 Maintain
02/11/2017 Broker: SunTrust Rating: Buy New Target: $57.0 Maintain

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. The company has market cap of $32.11 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. It has a 20.47 P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

The stock increased 2.41% or $1.23 during the last trading session, reaching $52.36. About 388,272 shares traded or 157.09% up from the average. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has risen 18.90% since April 17, 2017 and is uptrending. It has outperformed by 7.35% the S&P500.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>